cyrilzakka/clinical-trials huggingface dataset:
Effect of Extracorporeal Shock Waves on Hypertrophy Scar

Assess the effect of extracorporeal shock waves on hypertrophy scar

Prolonged and abnormal scarring after trauma, burns and surgical procedures often results in functional and cosmetic deformities. A wide variety of treatments have been advocated for pathologic scars regression. Unfortunately, the reported efficacy has been variable.Unfocused extracorporeal shock wave therapy is a feasible and non-intensive treatment. And it is an emerging option for the treatment of painful and retracting scars.

Administration of ESWT appears to result in significant improvements in scar clinical appearance, mobility and subjective pain. Clinical data were mirrored by histologic changes in connective tissue appearance and scar vascularization. Extracorporeal shock wave therapy is also an effective and conservative treatment for patients with aesthetic and functional sequela from burn scars. It is a feasible, cost-effective, well-tolerated treatment that can be used in the management of post-burn pathologic scars after the patients are briefed on the practical aspects of the treatment procedure.

Eligibility Criteria:
Inclusion Criteria:

1. aged between 18 \~ 65 years old;
2. at least 4 weeks since onset of onset of wound;
3. healing wound with at least 6 scores in Modified Vancouver Scar Scale for more than four weeks
4. the most important of all, read and signed the inform concern of this study.

Exclusion Criteria:

1. patients with open wound;
2. oxygen dependent
3. having evidence of cognitive deficit;
4. having local infection, severe inflammation or otherwise lesion that is not suggestive for ESWT;
5. patient with serious medical problems, as uncontrolled hypertension, coagulopathy, recent severe hemorrhage, neoplasm, severe hepatic disease, epilepsy, cutaneous pathology, mental retardation.
Prenatal Examination of Deletion 22q11 Syndrome : Thymic Dysgenesis THYMI Study

22q11.2 microdeletion seems the prenatally under-diagnosed . Indeed , there is a mismatch between the series on the heart rate of 22q11.2 antenatal 84% against 30% in the adult series despite a perinatal mortality of 16% suggesting opportunities for improvement in the prenatal diagnosis of fetus with a microdeletion 22q11.2 , especially without heart disease


Eligibility Criteria:
Inclusion Criteria:

* all prenatal diagnosis with FISH or CGH array of a fetal 22q11 deletion syndrome during the inclusion period.
* The pregnancy follow-up should be done one of the 44 french fetal medicine unit.
* Sonographic picture of 3 vessels slides should be communicated for independent review.

Exclusion Criteria:

* no sonographic picture available
Comparison of Cold Biopsy Forceps vs Cold Snare for Diminutive Colorectal Polyp Removal

European guidelines recommend the use of cold snare polypectomy (CSP) for removal of diminutive colorectal polyps (DCP)(5 mm or less). However, for DCP \< 4 mm cold biopsy forceps (CBF) may be optional. Moreover, CBF remains the endoscopist's technique of choice for polyp resection and CSP is associated with a failure of specimen retrieval for histology in up to 6.8% of cases. In this study, the investigators aimed to compare the efficacy of CSP with CBF for removal of DCP in routine colonoscopy


Eligibility Criteria:
Inclusion Criteria:

* Routine colonoscopy
* Patient older than 18 years
* at least one polyp measuring ≤ 5 mm

Exclusion Criteria:

* inflammatory bowel disease
* polyposis syndrome, pregnancy
* inability to provide informed consent
Bioavailability Of Lersivirine Single 750 Mg Tablet Versus 3 X 250 Mg Tablets

This is a randomized study to assess whether the pharmacokinetics of a new single 750 mg tablet is similar to 3 x 250 mg tablets (750 mg total).


Eligibility Criteria:
Inclusion Criteria:

* Healthy male and/or female subjects between the ages of 18 and 55 years, inclusive.
* Body Mass Index (BMI) of 17.5 to 30.5 kg/m2.
* Total body weight \>50 kg (110 lbs).

Exclusion Criteria:

* Treatment with an investigational drug within 30 days or 5 half-lives or local regulation (whichever is longer) preceding the first dose of study medication.
* Use of prescription or nonprescription drugs and dietary supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study medication.
* History of regular alcohol consumption exceeding 14 drinks/week for women and 21 drinks/week for men (1 drink = 150 mL of wine or 360 mL of beer or 45 mL of hard liquor).
Dehydroepiandrosterone Supplementation for Poor Responder Patients During in Vitro Fertilization Treatment

The aim of this study was to evaluate the effect of dehydroepiandrosterone supplementation on in vitro fertilization performance and outcome among poor-responder patient.


Eligibility Criteria:
Inclusion Criteria:

* previous poor response to ovarian stimulation in IVF.

Exclusion Criteria:

* patients over the age of 42
* patients who received DHEA at any time.
Traxi Panniculus Retractor for Cesarean Delivery

This prospective, open-label, randomized-controlled trial is designed to evaluate the use of the Traxi panniculus retractor-- a commercially available Class I FDA-exempt device will improve surgical outcomes, cardiopulmonary function, and provider/patient satisfaction in morbidly obese women undergoing cesarean delivery.

Morbidly obese women (BMI \>/= 40) undergoing non-emergent cesarean delivery will be recruited and randomized to Traxi panniculus retraction or standard of care for panniculus retraction.

The primary outcome evaluated will be operating time (incision to closure). Other secondary outcomes related to surgery including estimated blood loss, surgical site infection, and number of scrubbed personnel.

A secondary aim of the study is to evaluate the hypothesis that the Traxi retraction device reduces chestwall compression panniculus retraction and will improve intraoperative pulmonary function. To do this, the investigators will measure the difference in individual participant pulmonary function tests (forced vital capacity, forced expiratory volume) before and after panniculus retraction using a bedside spirometer.

A tertiary aim of the study is to evaluate the hypothesis that the Traxi retraction device will improve patient and provider satisfaction due to improved delivery experience and maintaining patient dignity. Patient and provider-reported outcomes will be evaluated using surveys.

Eligibility Criteria:
Inclusion Criteria:

* Pregnant
* BMI greater than or equal to 40 kg/m\^2
* Undergoing non-emergent cesarean delivery
* Able and willing to provide written, informed consent
* Singleton gestation

Exclusion Criteria:

* Fetal demise
* Disruption of abdominal skin (infection, rash, abrasion, laceration)
* Known adhesive allergy
Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia

To evaluate the safety and effectiveness of Aceclidine/Brimonidine (LNZ101) compared with Aceclidine (LNZ100) and vehicle in the treatment of Presbyopia.


Eligibility Criteria:
Inclusion Criteria:

1. Be able and willing to provide written informed consent and sign Health Information Portability and Accountability Act (HIPAA) form prior to any study procedure being performed;
2. Be able and willing to follow all instructions and attend study visits;
3. Be 45-75 years of age of either sex and any race or ethnicity at Visit 1;
4. Have +1.00 to -4.00 diopter(D) of sphere (so that spherical equivalent (SE) results in myopia no more severe than -4.00D MRSE. See Inclusion 5 below) in both eyes determined by manifest refraction documented at Visit 1;
5. Have ≤ 2.00D of cylinder (minus cylinder) in both eyes determined by manifest refraction documented at Visit 1;
6. Be presbyopic as determined at Visit 1

Exclusion Criteria:

1. Be a female of childbearing potential who is currently pregnant, nursing or planning a pregnancy;
2. Have known contraindications or sensitivity to the use of any of the study medications(s) or their components;
3. Have an active ocular infection at Visit 1 (bacterial, viral or fungal), positive history of an ocular herpetic infection, preauricular lymphadenopathy, or ongoing, active ocular inflammation (e.g., moderate to severe blepharitis, allergic conjunctivitis, peripheral ulcerative keratitis, scleritis, uveitis) in either eye;
4. Have moderate or severe dry eye defined as total corneal fluorescein staining at Visit 1;
5. Have clinically significant abnormal lens findings in either eye during dilated slit-lamp biomicroscopy and fundus exam documented within 3 months of Visit 1
The Effect of Dynamic Taping to Improve the Landing Strategy in Athletes.

This study will be conducted in three years: In the first year, we would recruit male and female high school soccer athletes to observe the effect of dynamic taping on landing error scoring system under fatigue status. In the second year, we would recruit junior high school, high school and college athlete to establish a native model of single-leg and double-leg LESS, then in advanced, confirm the ability to predict ACL injuries. In the third year, we will focus on high-risk subjects evaluated by LESS and athlete with ACL reconstruction to observe the supportive effect of dynamic taping.

ACL injuries occur most frequently in sports involving pivoting sudden deceleration. In Taiwan, it was estimated that at least 1,000 cases of patients require ACL reconstruction annually. Despite the improving of surgical technique, there is only 65% patients who received the ACL reconstruction return to their pre-injury level of sport. Therefore, to prevent ACL injuries in athletes is critical.

According to previous studies, the Landing Error Scoring System (LESS) is a clinical assessment tool to do field evaluation. We could predict the possibility of ACL injuries by the change of biomechanics. However, there are still many factors affecting the LESS, such as fatigue, single or double leg landing, age, sex and specific sport...etc., and comprehensive studies are absent.

Dynamic taping is a newly developing technique with better elasticity and extensibility. Studies showed that dynamic taping improve the biomechanics of knee joint. Hence, we can adjust the faulty movement as soon as possible to prevent the occurrence of ACL injuries.

This study will be conducted in three years: In the first year, we would recruit male and female high school soccer athletes to observe the effect of dynamic taping on landing error scoring system under fatigue status. In the second year, we would recruit junior high school, high school and college athlete to establish a native model of single-leg and double-leg LESS, then in advanced, confirm the ability to predict ACL injuries. In the third year, we will focus on high-risk subjects evaluated by LESS and athlete with ACL reconstruction to observe the supportive effect of dynamic taping.

Eligibility Criteria:
Inclusion Criteria:

* 1st Year: senior high school soccer athletes
* 2nd Year: junior/senior high school and college athlete
* 3dr Year: high-risk subjects evaluated by LESS and athlete with ACL reconstruction

Exclusion Criteria:

* Those who are unable to exercise due to acute joint, muscle or nerve injury in the lower extremities
* Lower extremity surgery within 1 year
* Head trauma within 6 months
* Those with vestibular injury within 6 months
* Allergic to Dynamic tape
* Pregnant
* Visual coordination impairment
Maxillary Anterior Teeth and Facial Index Parameters in Correlation with Recurring Esthetic Dental Proportion

The goal of this cross-sectional study is to state the inter relation between anthropometric parameters of pristine maxillary anterior teeth and facial index and their correlation with recurring esthetic dental proportion (RED) using 3D digital software (Medit) with intra intraoral scanner.The study comprised of 20 adult out patients with an equal number of males and females who had 20-35 years old.

The research focuses on analyzing the proportions of maxillary anterior teeth in relation to facial measurements, particularly within the Egyptian population. It evaluates how closely these dimensions align with the Recurring Esthetic Dental (RED) proportions, which suggest that the width of anterior teeth should decrease by a constant ratio moving distally. Using advanced digital tools such as the BELLUS 3D face scanner and MEDIT i700 intraoral scanner, the study collected detailed facial and dental measurements from participants to explore the correlation between facial index and tooth dimensions. The sample consisted of 20 participants (10 males and 10 females), with data analyzed using statistical methods to assess symmetry and gender variations in these proportions.). Moreover the results were statistically analyzed using the Independent t-test or an equivalent non-parametric test was used for comparison between the two groups, and the Pearson's correlation coefficient (r) test was used for correlating different parameters.

Eligibility Criteria:
Inclusion Criteria:

1. must be in the same age group (20-35). 2. free of systemically disease (GI, D.M., gastric influx). 3. Free of facial asymmetry. 4. Free of facial trauma or surgeries. 6.Normal Class 1 occlusion. 7. Free from any tooth wear disorder. 8.periodontally healthy without any previous orthodontic treatment. 9. Maxillary anterior teeth free from restoration

-

Exclusion Criteria:

1. History of surgery in the anterior maxillary or mandibular region. 2. Restorations in anterior sextant. 3 pregnant or lactating females. 4. gingival hyperplasia. 5. orthodontic treatment. 6. Facial asymmetry and clefts 7.Smokers patient

-
Chronic Coronary Syndrome Real Practice and Guidelines

Evaluate Adherence to the 2019 ESC Guidelines and standard care protocols for managing patients with the chronic coronary syndrome within the center

Coronary artery disease (CAD) refers to the presence of atherosclerotic plaques in the coronary arteries, Which can be non-obstructive or obstructive. It represents a major cause of morbidity, mortality, Hospitalization and health expenditure.

The most recent European Guidelines for the diagnosis and management of CCS delineate six common CCS scenarios: patients with suspected CAD and stable angina symptoms and/or dyspnea; patients with new onset of heart failure or left ventricular dysfunction and suspected CAD; asymptomatic and symptomatic patients with stabilized symptoms within one year after an acute coronary syndrome, or patients with recent revascularisation; asymptomatic and symptomatic patients beyond one year after initial diagnosis or revascularisation; Patients with angina and suspected vasospastic or microvascular disease; Asymptomatic subjects in whom CAD is detected at screening. Although these scenarios are heterogeneous, they are associated with an increased risk of acute events, and the stability of CCS patients over time depends on prompt diagnosis, optimal treatment and secondary prevention strategies, including Lifestyle modifications, and pharmacotherapy.

Eligibility Criteria:
Inclusion criteria

Adult patients (18 years or older) with a confirmed or suspected diagnosis of CCS, fall within one of the following broad CCS categories:

* Patients with angina and/or dyspnea, and suspected coronary artery disease.
* Patients with new onset of heart failure or reduced left ventricular function.
* Patients within 1 year after an acute coronary syndrome or recent revascularization.
* Patients beyond 1 year after initial diagnosis or revascularization.
* Patients with ANOCA (e.g., microvascular angina, vasospastic angina).
* Asymptomatic subjects referred for screening for coronary artery disease.

Exclusion Criteria:

* Patients with a recent acute coronary syndrome (defined as those within 1 month of a diagnosis of unstable angina, non-ST-segment elevation myocardial infarction or ST-segment elevation myocardial infarction)
Eye-tracking Investigation of Clinical Measures in Multiple Sclerosis

The overarching goal of this research protocol is to acquire eye-tracking, cognitive, and disease-severity metrics in MS patients to train machine learning algorithms that will support the development and performance assessment of a sensitive and non-invasive eye-tracking software application. The training of our machine learning classifying algorithms to identify which eye-tracking metrics-or combination thereof-can serve as reliable markers of MS disease severity and cognitive status.

This study will use a single group design in a cohort of MS patients. Eligible patients with MS will be selected and categorized based on their Expanded Disability Status Scale (EDSS) score. Patients eye movements will be captured using the patented eye-tracking technology at one single time point. In addition to the eye-tracking tests, patient phenotypes will be further detailed via brief functional and cognitive assessments using the EDSS, Brief International Cognitive Assessment for MS (BICAMS) and Multiple Sclerosis Functional Composite (MSFC). All patients will be required to participate in a single session.

Eligibility Criteria:
Inclusion Criteria:

* Able to provide informed consent
* Aged 18 years or older at the time of enrollment
* Able to read in either French or English
* Able to read the oculomotor task on-screen instructions at the testing distance (45cm) with or without corrective lenses
* Confirmed diagnosis of MS as per the Macdonald criteria, irrespective of MS subtype (relapsing-remitting (RRMS), secondary-progressive (SPMS), primary-progressive (PPMS), and progressive-relapsing (PRMS))
* Neurologist-determined EDSS score between 1.0-8.0

Exclusion Criteria:

* Evidence or medical history of psychiatric issues, which are known to also affect movements and oculomotor control
* Presence of comorbid neurological conditions to avoid eye movement anomaly confounds (Strabismus, cranial nerve palsy, stroke-causing hemianopsia)
* Diagnosis of macular edema or other pre-existing ocular conditions that would prevent a participant from performing the eye movement assessments
* Having started a new prescription medication or having changed the dose of a medication known to influence ocular motor visual function (e.g. benzodiazepines, antipsychotics and anticonvulsants) within the past three months
* Participants with non-disease related physical impairments to a leg, hand, or arm (e.g., broken bone or severe sprain) that would not allow completion of the assessments
Evaluation of 3D Ultrasound in Brain Tumor Surgery

Evaluation of impact of use of 3D ultrasound in brain tumor surgery on extend of resection. Benefit for surgery, neurological outcome, accuracy and image quality are secondary outcome parameters. Control group is a retrospective matched pair cohort.


Eligibility Criteria:
Inclusion Criteria:

* age above 18 suspected intra-axial lesion (metastasis or Glioma) potential gross total resection of lesion

Exclusion Criteria:

* no ability for informed consent
Mesenchymal Stromal Cells and Osteoarthritis

Osteoarthritis (OA) is one of the most frequent musculoskeletal disorders and represents the main indication for total joint arthroplasty. Multipotent mesenchymal stromal cells (MSCs) can be easily isolated and culture expanded from bone marrow aspirates and provide an excellent source of progenitor cells for cell-based regeneration strategies due to their ex vivo differentiation and proliferation capacity. Although there are hints that MSCs derived from OA patients may exhibit altered function the role of MSCs with respect to disease development and progression of OA is not clearly understood to date. To assess whether advanced-stage OA affects MSCs' suitability for musculoskeletal regenerative therapy, in the present study, we compare proliferation and differentiation potential of MSCs from osteoarthritic versus healthy donors.

Clinical data (range of motion of lower limb joints, sociodemographic score dataset, WOMAC score, EQ-5D score, Harris Hip Score, radiological evaluation (OA group only), routine laboratory parameters, and bone metabolism parameters)

Osteogenic, chondrogenic, and adipogenic differentiation is proofed qualitatively by cell staining

osteogenic, chondrogenic and adipogenic marker gene expression analysis using quantitative real-time RT-PCR

cell-specific alkaline phosphatase (ALP) activity assay

large-scale gene expression profile

Fluorescence-activated cell sorting (FACS)- CD44, CD105 (SH2; endoglin), CD106 (vascular cell adhesion molecule; VCAM-1), CD166, CD29, CD73 (SH3 and SH4), CD90 (Thy-1), CD117, STRO-1 and Sca-1 \[%\]

Eligibility Criteria:
Inclusion Criteria:

* indication for hip THR
* primary osteoarthritis of the hip
* Patient's consent

Exclusion Criteria:

* secondary osteoarthritis of the hip
* Any malignancies
* infectious disease
* rheumatic disease
* osteoporosis
* Any additional serious disease complicating the participation in this study
Head and Intraocular Trauma Tool for the Identification of Mild Traumatic Brain Injury

Rebion has developed a device, the Rebion trauma tool (referred to as the head and intraocular trauma tool, or "HITT"), that detects ocular fixation and alignment using a binocular retinal scan. Preliminary data obtained from hospitalized patients with a clinically-confirmed traumatic brain injury (TBI) and uninjured controls indicates that the device can detect changes in ocular fixation, alignment, and saccades that are related to brain injury. This study seeks to evaluate the ability of the Rebion trauma tool to assess perturbations in eye movements resulting from TBI. The study will enroll 100 TBI patients and 100 controls.


Eligibility Criteria:
Inclusion Criteria:

1. Age 13-45 years
2. Presents to the facility within 2 weeks of head trauma
3. Able to provide informed consent

   • If minor, then able to provide parental consent and minor assent
4. Able to participate in the examination, including the ability to follow simple instructions
5. Fluency in English or Spanish

Exclusion Criteria:

1. Glasgow Coma Scale score of equal to or less than 13 at the time of study enrollment
2. Under the influence of alcohol or drugs
3. Previous eye surgery
4. Visual acuity known to be 20/200 or less in either eye
5. Known strabismus, amblyopia (lazy eye), or double vision
6. Known eye movement disorder, including nystagmus
7. Known optic nerve disease, including papilledema or optic neuropathy
8. Known retinal disease, including macular degeneration or retinal degeneration
9. Known cataract
10. History of neurosurgery
11. History of stroke/brain hemorrhage, brain tumor, or epilepsy
12. Any head trauma requiring medical attention from a physician within the last 6 months
13. Diagnosed dementia or cognitive impairment requiring assistance for daily living
14. Other condition(s) under the care of a neurologist
15. Psychiatric hospitalization in the last 90 days
16. Subject considered unsuitable for participation in this clinical trial by PI, treating clinician, or study research staff
17. Any minor brain injury regardless of loss of consciousness